NOMIFENSINE MALEATE cas no:32795-47-4

NameNOMIFENSINE MALEATE
CAS32795-47-4
Synonyms1,2,3,4-tetrahydro-2-methyl-4-phenyl-8-isoquinolinamin(z)-2-butenedioate;1,2,3,4-tetrahydro-8-amino-2-methyl-4-phenyl-isoquinolinmaleate;8-amino-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinolinemaleate;alival(antidepressant);hoe984;hostalival;merital;meritalam
EINECS(EC#)251-223-7
Molecular FormulaC₁₆H₁₈N₂•C₄H₄O₄
Molecular Weight354.44

refractive index1.581

Hazardclass6.1(b)

Hazard Xn: Harmful;
Risk R22
Safety

Poison by ingestion, subcutaneous, intravenous, and intraperitoneal routes. Human systemic effects by intravenous route: heart rate changes, blood pressure elevation. Experimental reproductive effects. An antidepressant. When Nomifensine maleate (CAS NO.32795-47-4) is heated to decomposition, it emits toxic fumes of NO_x. See also NOMIFENSINE.

Hazard Codes Xn
Risk Statements 22-36/37/38
R22: Nomifensine maleate (CAS NO.32795-47-4) is harmful if swallowed. 
R36/37/38:Irritating to eyes, respiratory system and skin.
Safety Statements 26-36
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. 
S36:Wear suitable protective clothing.
RIDADR 3249
WGK Germany 3
RTECS NX4912800
HazardClass 6.1(b)
PackingGroup III

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
man	TDLo	intravenous	1429ug/kg/20M (1.429mg/kg)	CARDIAC: CHANGE IN RATE VASCULAR: BP ELEVATION NOT CHARACTERIZED IN AUTONOMIC SECTION ENDOCRINE: OTHER CHANGES	Clinical Pharmacology and Therapeutics Vol. 41, Pg. 88, 1987.
man	TDLo	oral	66429ug/kg/31 (66.429mg/kg)	BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY)	Canadian Medical Association Journal. Vol. 133, Pg. 207, 1985.
mouse	LD50	intraperitoneal	140mg/kg (140mg/kg)	BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: DYSPNEA	Oyo Yakuri. Pharmacometrics. Vol. 27, Pg. 1019, 1984.
mouse	LD50	intravenous	68mg/kg (68mg/kg)	BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: DYSPNEA	Oyo Yakuri. Pharmacometrics. Vol. 27, Pg. 1019, 1984.
mouse	LD50	oral	300mg/kg (300mg/kg)	BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: DYSPNEA	Oyo Yakuri. Pharmacometrics. Vol. 27, Pg. 1019, 1984.
mouse	LD50	subcutaneous	195mg/kg (195mg/kg)	BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: DYSPNEA	Oyo Yakuri. Pharmacometrics. Vol. 27, Pg. 1019, 1984.
rabbit	LD50	intravenous	> 32mg/kg (32mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES BEHAVIORAL: EXCITEMENT	Arzneimittel-Forschung. Drug Research. Vol. 23, Pg. 45, 1973.
rabbit	LD50	oral	854mg/kg (854mg/kg)	BEHAVIORAL: TREMOR BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Arzneimittel-Forschung. Drug Research. Vol. 23, Pg. 45, 1973.
rat	LD50	intraperitoneal	112mg/kg (112mg/kg)	BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: DYSPNEA	Oyo Yakuri. Pharmacometrics. Vol. 27, Pg. 1019, 1984.
rat	LD50	intravenous	66mg/kg (66mg/kg)	BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: DYSPNEA	Oyo Yakuri. Pharmacometrics. Vol. 27, Pg. 1019, 1984.
rat	LD50	oral	430mg/kg (430mg/kg)	BEHAVIORAL: TREMOR BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)	Arzneimittel-Forschung. Drug Research. Vol. 23, Pg. 45, 1973.
rat	LD50	subcutaneous	193mg/kg (193mg/kg)	BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: DYSPNEA	Oyo Yakuri. Pharmacometrics. Vol. 27, Pg. 1019, 1984.